Fondaparinux sodium: Anticoagulant factor Xa inhibitor treatment and prevention of deep vein thrombosis

Drugs of the Future

Volumn 27, Issue 2, 2002, Pages 122-131

  Reverter, J C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN COFACTOR II; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITOR COMPLEX; FOOD AND DRUG ADMINISTRATION; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

EID: 0036257889     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.02.656132     Document Type: Article

References (56)

1. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
2. Synthesis of heparin fragments: A α-methyl α-pentaoside with high affinity for antithrombin III
3. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent
4. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes
5. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
6. Structural studies on a biologically active hexasaccharide obtained from heparin
7. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III
8. Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide
9. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin
10. Regulation of thrombin activity by antithrombin and heparin
11. Structure and biological activity of heparin
12. The molecular-weight-dependence of the anti-coagulant activity of heparin
13. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
14. Role of the antithrombin-binding pentasaccharide in heparin acceleration of anti-thrombin-proteinase reactions: Resolution of the antithrombin conformational change contribution to heparin rate enhancement
15. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
16. Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31450) and standard heparin
17. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa
18. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins
19. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity
20. Free factor Xa is on the main pathway of thrombin generation in clotting plasma
21. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans
22. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt
23. Antithrombin mediated inhibition of factor Vlla-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to AT
24. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans
25. The synthetic pentasaccharide SR 90107A/Org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits
26. Effect of heparin and heparin fractions on platelet aggregation
27. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies
28. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia
29. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia
30. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: An experimental study in two models of thrombosis in the rabbit
31. Preliminary biochemical and pharmacological studies on a chemically synthesized pentasaccharide
32. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges
33. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non human primates
34. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis
35. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man
36. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: A pilot study in the setting of coronary angioplasty
37. Pharmacokinetic (PK) parameters of AT binding pentasaccharides in three animal species: Predictive value for humans
38. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times
39. The influence of renal function on the pharmacokinetics (PK) and pharmacodynamics of the novel antithrombotic agent Org31540/SR90107A
40. Fondaparinux sodium: A selective inhibitor of factorXa
41. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
42. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after after hip-fracture surgery
43. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
44. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The PENTATHLON 2000 Study
45. Efficacy of the first syntetic factor Xa inhibitor, pentasacchadde Org31540/SR90107A, with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The EPHESUS Study
46. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation
47. Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice
48. Setting a standard for venous thromboembolism prophylaxis
49. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: The PENTALYSE study
50. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
51. Recent advances in clinical trials of the direct and indirect selective factor Xa inhibitors
52. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats
53. Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat
54. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site
55. Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications